CD274 and neoplasm: Studies in animal models clearly demonstrate that abemaciclib and palbociclib synergize with anti-PD-1 and PD-L1 antibodies to induce tumor regression, and in some cases complete regression, in immunocompetent mouse models of lung [172] and mammary tumors [159, 160, 173, 174].